Magnetar Financial’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Magnetar Financial’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-436,995	Closed	-$4.38M	–	1227
2022 Q3	$4.38M	Buy	436,995 +374,296	+597%	+$3.73M	0.06%	357
2022 Q2	$621	Buy	62,699 +48,875	+354%	+$483K	0.01%	1090
2022 Q1	$136K	Sell	13,824 -7,200	-34%	-$70.7K	﹤0.01%	1100
2021 Q4	$205K	Hold	21,024	–	–	﹤0.01%	1149
2021 Q3	$206K	Buy	21,024 +9,224	+78%	+$89.9K	﹤0.01%	1084
2021 Q2	$116	Buy	+11,800	New	+$116K	﹤0.01%	1146

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Magnetar Financial's EUCR Position: Q4 2022 in Review

Magnetar Financial sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 436,995 shares — an estimated $4.38M sold.

Magnetar Financial first reported a position in EUCR in Q2 2021 and held it in 6 quarters. The position peaked at $4.38M in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

Magnetar Financial reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Magnetar Financial sold 436,995 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $4.38M.
Magnetar Financial first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q2 2021 and held it in 6 quarters.
Magnetar Financial's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $4.38M in Q3 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Magnetar Financial's 13F filing for Q4 2022, filed 14 Feb 2023.